Revatio Named as new Pfizer PPH Treatment

In December 2004 Pfizer Inc submitted regulatory filings in the United States and Europe for Revatio (sildenafil citrate) as a treatment for pulmonary hypertension. According to the filing, clinical trials conducted throughout the world showed sildenafil 20 mg taken three times a day is effective in treating patients with PPH. These patients showed improved physical ability as measured by increased walking distance over a six minute time interval. These PPH Patients on (Revatio) sildenafil also showed a reduction in blood pressure in arteries of the lungs and an increase in cardiac (heart) output.

These early findings demonstrate promise and larger clinical trials using (Revatio) sildenafil as a treatment of pulmonary hypertension are being developed.

More on sildenafil >>


Learn about New Treatments and Get Research Updates.
Although Pulmonary Hypertension cannot be cured using existing medicine. It can be controlled with new drugs and therapies.

Learn More about your rights to medical care and bill payment assistance>>


Pulmonary Hypertension Treatments

Return to Home Page